These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6695282)

  • 21. Measures of the inflammatory response in cryptogenic fibrosing alveolitis.
    Pantin CF; Valind SO; Sweatman M; Lawrence R; Rhodes CG; Brudin L; Britten A; Hughes JM; Turner-Warwick M
    Am Rev Respir Dis; 1988 Nov; 138(5):1234-41. PubMed ID: 3144213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term changes of some ventilatory and respiratory functions in cryptogenic fibrosing alveolitis (author's transl)].
    Fucík J; Ouredník A
    Cas Lek Cesk; 1974 Sep; 113(36):1091-4. PubMed ID: 4410039
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential limitations of clinical criteria for the diagnosis of idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.
    Peckham RM; Shorr AF; Helman DL
    Respiration; 2004; 71(2):165-9. PubMed ID: 15031572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosing alveolitis predating microscopic polyangiitis.
    Becker-Merok A; Nossent JC; Ritland N
    Scand J Rheumatol; 1999; 28(4):254-6. PubMed ID: 10503564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom.
    Johnston ID; Gomm SA; Kalra S; Woodcock AA; Evans CC; Hind CR
    Eur Respir J; 1993 Jun; 6(6):891-3. PubMed ID: 8339811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study.
    Hubbard R; Venn A; Smith C; Cooper M; Johnston I; Britton J
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):743-7. PubMed ID: 9517585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of increased histamine levels of lung lavage fluids from patients with cryptogenic fibrosing alveolitis.
    Haslam PL; Cromwell O; Dewar A; Turner-Warwick M
    Clin Exp Immunol; 1981 Jun; 44(3):587-93. PubMed ID: 7326869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival.
    Rudd RM; Prescott RJ; Chalmers JC; Johnston ID;
    Thorax; 2007 Jan; 62(1):62-6. PubMed ID: 16769717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival.
    Turner-Warwick M; Burrows B; Johnson A
    Thorax; 1980 Aug; 35(8):593-9. PubMed ID: 7444826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothesis: exposure to solvents may cause fibrosing alveolitis.
    Billings CG; Howard P
    Eur Respir J; 1994 Jun; 7(6):1172-6. PubMed ID: 7925888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of cryptogenic fibrosing alveolitis.
    Tukiainen P; Taskinen E; Holsti P; Korhola O; Valle M
    Thorax; 1983 May; 38(5):349-55. PubMed ID: 6879483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial cryptogenic fibrosing alveolitis: a case report.
    Stinson JC; Tomkin GH
    Ir J Med Sci; 1992 Feb; 161(2):42-3. PubMed ID: 1517052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pulmonary function in diffuse fibrosing alveolitis (author's transl)].
    Yernault JC; Englert M; Jonghe MD; Coster AD
    Acta Tuberc Pneumol Belg; 1974; 65(6):594-600. PubMed ID: 4466348
    [No Abstract]   [Full Text] [Related]  

  • 34. Cryptogenic fibrosing alveolitis associated with peripheral neuropathy.
    Turton C; Jacobs JM
    Q J Med; 1983; 52(207):417-23. PubMed ID: 6316400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
    J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens.
    Bateman ED; Turner-Warwick M; Haslam PL; Adelmann-Grill BC
    Thorax; 1983 Feb; 38(2):93-101. PubMed ID: 6344313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediastinal lymphadenopathy in cryptogenic fibrosing alveolitis: the effect of steroid therapy on the prevalence of nodal enlargement.
    Franquet T; Gimenez A; Alegret X; Rodriguez-Arias JM
    Clin Radiol; 1998 Jun; 53(6):435-8. PubMed ID: 9651059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology.
    Moolman JA; Bardin PG; Rossouw DJ; Joubert JR
    Thorax; 1991 Aug; 46(8):592-5. PubMed ID: 1926031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryptogenic fibrosing alveolitis: have we made any progress?
    Lake FR
    Respirology; 1996 Dec; 1(4):227-32. PubMed ID: 9441111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrosing alveolitis in infancy and childhood.
    Hewitt CJ; Hull D; Keeling JW
    Arch Dis Child; 1977 Jan; 52(1):22-37. PubMed ID: 836051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.